Drug Trial Radar · NCT05626114
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 23, 2023
Primary completion
Mar 1, 2031
Study completion Mar 1, 2031
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfilled the eligibility requirements for the parent study and meet the substudy's eligibility criteria will have the option to participate in the substudy. The EarlySight Cellularis® Discovery device will be used only as an assessment tool and data obtained from this device will not be used to guide clinical care or influence clinical outcomes for participants.
Conditions
- Geographic Atrophy
Interventions
OpRegenBiological
OpRegen dose of up to approximately 200,000 cells will be delivered into the subretinal space.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Subretinal Surgical Delivery of OpRegen to Target RegionsTime frame: 3 months post-surgery
- Incidence and Severity of Procedure-related Adverse Events (AEs) at 3 Months Following SurgeryTime frame: 3 months post-surgery
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Retina-Vitreous Associates Medical Group
Beverly Hills, California · Recruiting
Retinal Consultants Medical Group
Sacramento, California · Recruiting
West Coast Retina
San Francisco, California · Recruiting
Retina Vitreous Associates of Florida
St. Petersburg, Florida · Recruiting
The Retina Care Center
Baltimore, Maryland · Recruiting
The Retina Institute
St Louis, Missouri · Recruiting
Sierra Eye Associates
Reno, Nevada · Recruiting
Duke Eye Center
Durham, North Carolina · Recruiting
Cincinnati Eye Institute
Blue Ash, Ohio · Recruiting
Mid Atlantic Retina
Philadelphia, Pennsylvania · Recruiting
Tennessee Retina PC
Nashville, Tennessee · Recruiting
Austin Clinical Research, LLC
Austin, Texas · Recruiting
Retina Consultants of Texas
Bellaire, Texas · Recruiting
Piedmont Eye Center
Lynchburg, Virginia · Recruiting
Spokane Eye Clinical Research;Spokane Eye Surgery Center
Spokane, Washington · Recruiting
Hadassah MC
Jerusalem, Israel · Recruiting
Tel Aviv Sourasky MC
Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.